CStone Pharmaceuticals-B's stock fell 5.17% during intraday trading on Tuesday, reflecting significant selling pressure on the pharmaceutical company.

The decline is attributed to a dual overhang of substantial equity dilution and deteriorating financial fundamentals. The company recently completed a placement of 118 million new shares at HK$8.97 per share, a notable discount to the prevailing market price, raising approximately HK$1.053 billion and diluting existing shareholders. This transaction expanded the total issued share capital by approximately 7.99%.

Compounding the negative sentiment, the company disclosed annual results showing revenue declined by 33.8% year-over-year, primarily due to lower commercialization and licensing income. The annual net loss widened sharply from approximately RMB 91 million to RMB 437 million, driven by a surge in R&D expenditure to fund accelerated clinical trials and new drug programs. The combination of equity dilution and mounting operating losses has weighed heavily on investor confidence.